INT-747: Phase II data

In a double-blind, U.S. Phase II trial in 64 patients, INT-747 met the primary endpoint of significantly improving insulin sensitization as measured by glucose disposal rate (GDR) at 6 weeks vs. placebo after high-dose insulin infusions (0.49 vs. -0.51 mg/kg/min, p<0.05) and low-dose insulin infusions (0.59 vs. -0.61 mg/kg/min, p<0.05). Patients received placebo, 25 or 50 mg INT-747 once daily for 6 weeks. The low dose of INT-747 also met the primary endpoint, but the high dose did not. ...